A Phase 2a Study of AdV-tk [cancer gene therapy] + Valacyclovir [valciclovir] Gene Therapy in Combination With Standard Radiation Therapy for Malignant Glioma.

Trial Profile

A Phase 2a Study of AdV-tk [cancer gene therapy] + Valacyclovir [valciclovir] Gene Therapy in Combination With Standard Radiation Therapy for Malignant Glioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Advantagene
  • Most Recent Events

    • 06 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 03 Mar 2016 Therapeutic use has been added to Trial focus; Secondary outcome of Overall survival has been made primary outcome and time frame has been extended from 24 months to 5 years as per ClinicalTrials.gov record.
    • 03 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top